Iloprost Waymade (Iloprost)

Iloprost is a selective prostacyclin (PGI2) receptor agonist. By binding to these receptors on vascular smooth‑muscle cells, it stimulates adenylate cyclase, raises intracellular cyclic‑AMP, and causes vasodilation while also inhibiting platelet aggregation, thereby improving blood flow in the pulmonary circulation and peripheral microvasculature.

The dosing regimen for Iloprost Waymade is individualized. A qualified prescriber determines the appropriate dose, infusion rate, and treatment schedule based on the patient’s clinical condition, response, and tolerance. Specific dosing details should be obtained from the prescribing physician.

Safety data for Iloprost in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if required), and the necessary import documentation.

Iloprost and other prostacyclin analogues such as epoprostenol share a similar mechanism of vasodilation and platelet inhibition. Iloprost is administered intravenously and has a relatively short half‑life, allowing for controlled infusion, whereas epoprostenol often requires continuous infusion. Choice of therapy depends on clinical response, tolerability, and logistical considerations.

Iloprost Waymade should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Once removed from refrigeration, use the preparation within the time frame specified in the product labeling.

Iloprost Waymade is given by intravenous infusion. The infusion is typically performed in a clinical setting under medical supervision, with the rate and duration adjusted according to the prescriber’s instructions and the patient’s tolerance. Monitoring of vital signs during and after the infusion is standard practice.

The most serious adverse events include severe hypotension, pulmonary edema, significant bleeding, and allergic reactions such as anaphylaxis. Patients should be monitored closely for sudden drops in blood pressure, respiratory distress, signs of bleeding, or any hypersensitivity symptoms during and after infusion.

Iloprost is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation, in those with severe uncontrolled hypotension, recent myocardial infarction, or active bleeding disorders. Caution is also advised for individuals with significant hepatic or renal impairment, and the drug should be avoided in pregnancy unless absolutely necessary.